BioPharmSignal logoBioPharmSignal

Biotech News

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou (CRBU)CaribouCompany update

BERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences: Citi 2026 Virtual Oncology Leadership Summit,

Open original release

Related news

CRBUCaribou2026-05-13 20:05 EST

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

CRBUCaribou2026-05-27 20:05 EST

Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

SRPTSarepta Therapeutics2026-06-01 20:30 EST

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

CRSPCRISPR Therapeutics2026-05-28 12:00 EST

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

RLAYRelay Therapeutics2026-05-27 20:05 EST

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

ZNTLZentalis2026-05-13 20:05 EST

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

EXELExelixis2026-05-27 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

ARGXArgenx2026-05-27 05:00 EST

argenx to Present at Upcoming Investor Conferences

ELVNEnliven Therapeutics2026-05-21 20:05 EST

Enliven Therapeutics to Present at Upcoming Investor Conferences

SNDXSyndax Pharmaceuticals2026-05-20 11:00 EST

Syndax Announces Participation in Upcoming Investor Conferences

View all latest news

Caribou

Caribou Biosciences is a gene-editing company focused on CRISPR-based cell therapies and oncology applications. The company is trying to make edited cell therapy more effective and scalable.

Recent company news

CRBUCaribou2026-05-27 20:05 EST

Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

CRBUCaribou2026-05-13 20:05 EST

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

CRBUCaribou2026-05-12 13:30 EST

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

CRBUCaribou2026-05-07 20:06 EST

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

CRBUCaribou2026-05-05 20:05 EST

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

Stock data

Close
1.59 USD
Market cap
230.1M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States